BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, today announced its participation in the 14th World Clinical Biomarkers & CDx Summit 2024, taking place September 3 – 6 in Boston, Massachusetts. The event will bring together drug developers, diagnostics providers, and payers to advance biomarker-driven clinical trials, focusing on early biomarker discovery, clinical strategy optimization and the commercialization of precision therapies. BostonGene will also exhibit at booth #19.
During the event, BostonGene will deliver a talk on advancing immunotherapy trials’ future.
Designing More Effective Trials with Integrated Immune Profiling of Peripheral Blood and Tumor Tissue
- Date and time: Friday, September 6 | 2:35 PM
- Speaker: Michael Goldberg, PhD, VP of R&D, BostonGene
This session will explore critical aspects of immunotherapy, specifically identifying immunological signatures that can optimize the alignment of treatments with their mechanisms of action. Topics include immune system profiling to evaluate patients’ immune system status, reveal underlying resistance to therapies and enable personalized treatment approaches. The discussion will also delve into the transcriptional profiling of peripheral immune cells and circulating cell-free RNA, which has the potential to uncover vital prognostic biomarkers that are key for predicting drug responses and making real-time treatment decisions.
“Immunotherapy holds transformative potential in oncology, but its success depends on our ability to match the right patients with the right therapies. Our AI-powered platform enables comprehensive immune system profiling to identify key immunological signatures and resistance factors, empowering clinicians to make personalized treatment decisions. Our ultimate goal is to improve patient outcomes by guiding therapies in real-time,” said Michael Goldberg, PhD, VP, Research & Development at BostonGene.
About BostonGene Corporation
BostonGene is a company at the intersection of technology and biology, dedicated to advancing and personalizing cancer medicine. Founded in 2015, BostonGene has continually pushed the boundaries of innovation to improve cancer patient care and accelerate research and drug development through cutting-edge solutions. Leveraging our AI-powered multiomics platform, we digitize and comprehensively analyze the molecular profiles of cancer patients, including the immune system and tumor microenvironment. Our software solutions, indication-specific cancer library and advanced bioanalytics, enable us to discover multiparametric signatures, identify targets, match them to relevant indications for biopharma and recommend the most effective treatments for patients. For more information, visit www.BostonGene.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240828010978/en/